Deerfield Management Company, L.P. (Series C) Larimar Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.37 Billion
- Q3 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 30,606,974 shares of LRMR stock, worth $103 Million. This represents 1.84% of its overall portfolio holdings.
Number of Shares
30,606,974
Previous 21,231,974
44.16%
Holding current value
$103 Million
Previous $61.4 Million
61.11%
% of portfolio
1.84%
Previous 1.41%
Shares
5 transactions
Others Institutions Holding LRMR
# of Institutions
153Shares Held
89MCall Options Held
6.44MPut Options Held
622K-
Ra Capital Management, L.P. Boston, MA6.05MShares$20.4 Million0.34% of portfolio
-
Blue Owl Capital Holdings LP New York, NY5.85MShares$19.8 Million8.2% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.9MShares$16.6 Million0.01% of portfolio
-
Opaleye Management Inc. Boston, MA3.72MShares$12.6 Million2.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$11.5 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $146M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...